th America th America

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers.

The Understanding, Prevention and Control of Human Cancer is an account of how a married couple opened understanding of environmental carcinogenesis. Elizabeth Cavert and James A. Miller showed that enzymes of the human body activate and enable otherwise benign organic chemicals to combine with DNA in such a manner that cancer results. Their work is of particular note because cancer causes more loss of life-years than the sum of all other causes of death-and, as the President's (USA) Cancer Panel warned, environmental carcinogenesis is a form of cancer that has been previously "grossly underestimated". The Millers' cancer research led to tests that identify dangerous chemicals which in turn permits prevention and thus the control of human cancer.

In this issue of Neuroimaging Clinics, guest editors Salmaan Ahmed and J. Matthew Debnam bring their considerable expertise to the topic of Thyroid and Parathyroid Imaging. Provides in-depth, clinical reviews on Thyroid and Parathyroid Imaging, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

Visceral Leishmaniasis: Therapeutics and Vaccines describes current therapeutics, natural anti-leishmanial molecules, anti-leishmanial screening, and explores vaccine candidates and amastigote-based vaccination strategies for Leishmania. The book provides a precise view on VL, Leishmania parasite culture, host immunity and immunomodulation, natural compounds effective against VL, animal models for VL, and methodologies available for anti-leishmanial drug screening procedures against VL, as well as vaccine and vaccination-related information on Leishmaniasis. Readers will find concrete information on past and current hurdles facing vaccine development for Leishmania, along with scientific opportunities and the potential impact of vaccines, including problems encountered. The book is designed to increase the understanding of vaccines, particularly in VL, for students and researchers. Although vaccines are now available for many diseases, there are still challenges ahead for a vaccine for VL. The ideal vaccine must be safe and able to induce an immune response that is strong and effective. In a nutshell, a combination of chemotherapy (drugs) and immunoprophylaxis (vaccine) would be ideal to win the battle against VL.

Volume 37 will provide details on the major chemical constituents of medicinal plants and their mechanism of action as the anticancer compounds. This special issue, in addition to the previous volume (volume 36 of The Enzyme series was on Natural Products and Cancer Signaling Targets: Isoprenoids, Polyphenols and Flavonoids), will highlight the significant advance made in the field in elucidating mechanisms of anticancer effect of the major phytochemicals.

Foundations of Colorectal Cancer provides a holistic and comprehensive dive into colorectal cancer, discussing the contributions of each discipline that studies it, allowing its understanding from the most demographic and ethical facts, to the treatment process, its varieties and genetic background. Written by experts in diverse areas such as cancer research, oncology, genetics, biochemistry, psychology, social sciences, bioinformatics and palliative care, the book brings real-world experiences to help readers with any challenge they may face when dealing with patients or during their research workflow. The content is split into nine sections: Clinical manifestations and disease detection, covering primary and secondary prevention, and the role of primary care; Diagnosis and staging, discussing endoscopy, colonoscopy, molecular pathology, and anatomopathological diagnosis; Treatment, including endoscopic, surgical, radiological, and postoperative approaches; Molecular and biological mechanisms, with the role of intestinal microbiota, stem cells and signaling pathways; New diagnostic methods, encompassing biomarkers and bioinformatics tools for research; Biobanks, with an overview of their regulations and importance in the research; Epidemiological studies, focusing on incidence and mortality globally and by regions; Hereditary colorectal cancer, differentiating nonpolyposis and polyposis types; and Addressing the consequences of colorectal cancer, covering psychological effects, nutrition and ethical issues.

This issue of PET Clinics focuses on Total Body PET Imaging, and is edited by Drs. Lorenzo Nardo, Ramsey Badawi, Joel S. Karp and Austin Pantel. Articles will include: UC Davis update on the uEXPLORER; Zhongshan update on the uEXPLORER; UPenn update on the PennPET Explorer; Total body imaging instrumentation design considerations; 3D/4D reconstruction and quantitative total body imaging; Analysis of 4D data for total body imaging; Total body imaging and cancer; Total body imaging and metabolic disease; Total body imaging and infection; Total body imaging and musculoskeletal disease; Total body imaging and cardiovascular disease; Total body imaging and cardiac applications; Total body imaging and neuroimaging; and more!

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges.

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.